OncoMatch/Clinical Trials/NCT07344311
A Phase I Trial of A-CAR032 in Participants With mCRPC
Is NCT07344311 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies dnTGFβRII-armoured STEAP2-targeted autologous CAR T-Cell for prostate cancer.
Treatment: dnTGFβRII-armoured STEAP2-targeted autologous CAR T-Cell — This FTiH, single-arm, open-label, investigator-initiated Phase I trial will evaluate the safety, antitumour activity, CK/pharmacodynamics (PD), biomarkers, immunogenicity, and feasibility of A-CAR032 in adult participants with mCRPC, who have previously progressed after ARPI treatment of prostate cancer (whether before or in the metastatic castration-resistant setting) and, in the judgment of the investigator, are ineligible for standard treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Biomarker criteria
Required: STEAP2 expression (tumor material required for retrospective assessment)
Consent and provision of tumour material to assess STEAP2 expression and other correlative biomarkers retrospectively with pre- and post-treatment biopsies
Disease stage
Metastatic disease required
Prior therapy
Must have received: androgen receptor pathway inhibitor (abiraterone, enzalutamide, apalutamide, darolutamide, rezvilutamide)
Participant has previously received an ARPI (ie, abiraterone, enzalutamide, apalutamide, darolutamide, rezvilutamide) whether before or in the metastatic castration-resistant setting
Cannot have received: CAR-T cell therapy
Prior treatment with: Any CAR-T therapy
Cannot have received: STEAP2-targeted therapy
Prior treatment with: Any therapy that is targeting STEAP2
Lab requirements
Blood counts
adequate organ and marrow function
Kidney function
adequate organ and marrow function
Liver function
adequate organ and marrow function
Adequate organ and marrow function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify